- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04615845
A Phase 1 Study of Autologous Dendritic Cell Immunotherapy in Patients With mCRPC
Un estudio abierto, de un solo centro, de fase 1 para evaluar la seguridad de la inmunoterapia contra el cáncer con células dendríticas autólogas en pacientes con cáncer de próstata metastásico resistente a la castración (CPRCm)
The goal of this clinical trial was to evaluate the safety of Cellgram-DC-PC, an autologous dendritic cell-based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
Cellgram-DC-PC is an autologous dendritic cell-based cancer immunotherapy developed for patients with metastatic castration-resistant prostate cancer (mCRPC). This was a Phase 1, single-center, open-label clinical trial designed to characterize the safety profile of Cellgram-DC-PC following administration in patients with mCRPC.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Seoul, Corea del Sur
- Asan medical center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
19 and under 80 years
-
Histologically confirmed prostate adenocarcinoma
-
Patients with stage M1a or M1b with extrapelvic lymph nodes and bone metastases
-
Patients diagnosed with castration-resistant prostate cancer after failure of male hormone deprivation therapy (Castrate levels of testosterone <50 ng/dL) and If either a or b is satisfied:
- Biochemical progression: Prostate Specific Antigen (PSA) increases three times in a row at 1 week intervals, two 50% increases compared to the lowest point, PSA> 2ng/mL, or
- Radiological progression: appearance of new lesions; 2 or more new lesions on the bone scan
-
Asymptomatic or mild patients after previous treatment
- Patients who have not used narcotic analgesics within 21 days prior to enrollment
- Patients with an average weekly pain of less than 4 on the Visual Analogue Scale(VAS) (out of 10)
-
Combination of Luteinizing hormone-releasing hormone(LHRH) analogs (leuprolide (Lupron, Viadur, Eligard) and goserelin (Zoladex, etc.) for the inhibition of gonadotropin is allowed
-
Whole body performance status: European Cooperative Oncology Group(ECOG) 0~1
-
Patients whose life expectancy is at least 6 months or longer
-
Hb ≥ 8.0g/dL, Absolute Neutrophil Count(ANC) ≥ 1,500/mm3, Platelets ≥ 100,000/mm3
-
Serum Creatinine ≤ 2.0 x Upper Limit of Normal(ULN) or Calculated Creatinine Clearance > 30mL/min
-
Total Bilirubin ≤ 1.5 x ULN or Direct bilirubin ≤ ULN, Aminotransferase (AST)/Alanine aminotransferase(ALT) <2.5 x ULN
-
Patients who did not receive surgery, radiation therapy, or immunotherapy within the last 6 weeks and recovered from side effects
-
Patients who agreed to use medically recognized contraceptive methods during the clinical trial participation period
-
Patients who voluntarily participated in clinical trials and signed the Informed Contents Form (ICF)
Exclusion Criteria:
- Patients who have a local recurrence and are scheduled for local treatment.
- Patients with malignant tumors other than non-melanoma skin cancer in the past 3 years
- Patients with visceral metastases (metastases to the lungs, liver, adrenal glands, peritoneum, brain, etc.)
- Patients who previously received anti-tumor immunotherapy (anti-PD1, anti-PDL1 or anti-PDL2, etc.) or participated in immunotherapy-related clinical trials
- Patients with active autoimmune diseases requiring systemic immunosuppression treatment (e.g., immunosuppressants such as cyclosporin A or azathioprine or steroids for disease control)
- Patients with medical conditions requiring continuous or intermittent administration of systemic steroids or immunosuppressants
- Patients who received blood products (limited to whole blood products) within 4 weeks of screening criteria, or patients who received colony stimulating factors (Colony Stimulating Factor or recombinant Erythropoietin)
- Patients with a history of organ or hematopoietic stem cell transplantation
- Patients with acute or chronic infections requiring systemic treatment
- Patients known to be infected with human immunodeficiency virus (HIV)/serum positive
- Patients with active hepatitis A, B or C
- Patients with untreated syphilis (Fluorescent Treponemal Antibody Absorption Test (FTA-ABS) Immunoglobulin M positive patients)
- Patients expected to require therapeutic biotherapy or immunotherapy
- Patients who received live virus vaccines (e.g. measles, mumps, rubella, chickenpox, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), oral typhoid vaccine, Flu-Mist, etc.) within 30 days
- Patients with a history of anaphylaxis to gentamicin
- Others, if the person in charge of the study determines that it is not suitable for the clinical trial
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Cellgram-DC-PC
Participants received Cellgram-DC-PC by subcutaneous injection near the inguinal lymph nodes. |
Patients received three subcutaneous injections of Cellgram-DC-PC (autologous dendritic cells) near the inguinal lymph nodes at Weeks 0, 2, and 4.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Adverse Event
Periodo de tiempo: From informed consent to the end of treatment at Week 28.
|
Adverse events (AEs) were assessed for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. |
From informed consent to the end of treatment at Week 28.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Immune Response
Periodo de tiempo: At baseline (Week 0), Week 4, Week 8, Week 16, and Week 28.
|
Tumor antigen-specific immune responses were evaluated by measuring changes in serum IFN-γ and IL-12 levels and antigen-specific T-cell responses following administration of the investigational product. |
At baseline (Week 0), Week 4, Week 8, Week 16, and Week 28.
|
|
Change in Prostate-Specific Antigen (PSA)
Periodo de tiempo: At baseline (Week 0), Week 2, Week 4, Week 8, Week 16, and Week 28.
|
Exploratory efficacy was evaluated by measuring changes in prostate-specific antigen (PSA) levels from pre-treatment (Week 0) to post-treatment assessment. |
At baseline (Week 0), Week 2, Week 4, Week 8, Week 16, and Week 28.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: BUMJIN LIM, Ph.D, Asan Medical Center
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- PMC-DC-01
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Individual participant data will not be made available to other researchers.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .